SG11201510166YA - Compositions and methods of immunizing against c. difficile - Google Patents
Compositions and methods of immunizing against c. difficileInfo
- Publication number
- SG11201510166YA SG11201510166YA SG11201510166YA SG11201510166YA SG11201510166YA SG 11201510166Y A SG11201510166Y A SG 11201510166YA SG 11201510166Y A SG11201510166Y A SG 11201510166YA SG 11201510166Y A SG11201510166Y A SG 11201510166YA SG 11201510166Y A SG11201510166Y A SG 11201510166YA
- Authority
- SG
- Singapore
- Prior art keywords
- difficile
- compositions
- methods
- immunizing against
- immunizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835246P | 2013-06-14 | 2013-06-14 | |
| PCT/US2014/042298 WO2014201346A1 (en) | 2013-06-14 | 2014-06-13 | Compositions and methods of immunizing against c. difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510166YA true SG11201510166YA (en) | 2016-01-28 |
Family
ID=51168412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510166YA SG11201510166YA (en) | 2013-06-14 | 2014-06-13 | Compositions and methods of immunizing against c. difficile |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9730994B2 (en) |
| EP (1) | EP3007724B1 (en) |
| JP (1) | JP6691477B2 (en) |
| KR (1) | KR20160020543A (en) |
| CN (1) | CN105611942A (en) |
| AU (1) | AU2014277981B2 (en) |
| BR (1) | BR112015031088A2 (en) |
| CA (1) | CA2915279A1 (en) |
| MX (1) | MX2015017257A (en) |
| SG (1) | SG11201510166YA (en) |
| TW (1) | TWI648063B (en) |
| WO (1) | WO2014201346A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2754446C2 (en) | 2011-04-22 | 2021-09-02 | ВАЙЕТ ЭлЭлСи | Compositions related to mutant toxin clostridium difficile and their application methods |
| BR122016023101B1 (en) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR102625114B1 (en) * | 2017-09-28 | 2024-01-12 | 화이자 인코포레이티드 | Compositions and methods for eliciting an immune response against Clostridium difficile |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| WO1999020304A1 (en) * | 1997-10-20 | 1999-04-29 | Oravax, Inc. | Passive immunization against clostridium difficile disease |
| HUE037932T2 (en) * | 2007-09-14 | 2018-09-28 | Sanofi Pasteur Biologics Llc | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| RU2754446C2 (en) | 2011-04-22 | 2021-09-02 | ВАЙЕТ ЭлЭлСи | Compositions related to mutant toxin clostridium difficile and their application methods |
| AR089797A1 (en) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| JP2016516721A (en) | 2013-03-15 | 2016-06-09 | サノフィ パストゥール インコーポレイテッド | Toxoids, compositions and related methods |
| BR112015023469A8 (en) | 2013-03-15 | 2019-12-03 | Sanofi Pasteur Inc | related toxoids, compositions and methods |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
-
2014
- 2014-06-13 SG SG11201510166YA patent/SG11201510166YA/en unknown
- 2014-06-13 WO PCT/US2014/042298 patent/WO2014201346A1/en active Application Filing
- 2014-06-13 BR BR112015031088A patent/BR112015031088A2/en not_active Application Discontinuation
- 2014-06-13 KR KR1020167001130A patent/KR20160020543A/en not_active Application Discontinuation
- 2014-06-13 MX MX2015017257A patent/MX2015017257A/en unknown
- 2014-06-13 EP EP14737429.2A patent/EP3007724B1/en active Active
- 2014-06-13 CA CA2915279A patent/CA2915279A1/en not_active Abandoned
- 2014-06-13 JP JP2016519675A patent/JP6691477B2/en active Active
- 2014-06-13 CN CN201480044768.7A patent/CN105611942A/en active Pending
- 2014-06-13 US US14/897,870 patent/US9730994B2/en active Active
- 2014-06-13 AU AU2014277981A patent/AU2014277981B2/en not_active Ceased
- 2014-06-16 TW TW103120772A patent/TWI648063B/en not_active IP Right Cessation
-
2017
- 2017-07-10 US US15/645,057 patent/US20170304423A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,278 patent/US20200113991A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,486 patent/US11419930B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9730994B2 (en) | 2017-08-15 |
| BR112015031088A2 (en) | 2017-07-25 |
| JP6691477B2 (en) | 2020-04-28 |
| MX2015017257A (en) | 2016-11-11 |
| EP3007724B1 (en) | 2023-07-05 |
| WO2014201346A1 (en) | 2014-12-18 |
| EP3007724A1 (en) | 2016-04-20 |
| CA2915279A1 (en) | 2014-12-18 |
| US11419930B2 (en) | 2022-08-23 |
| JP2016521754A (en) | 2016-07-25 |
| TWI648063B (en) | 2019-01-21 |
| KR20160020543A (en) | 2016-02-23 |
| CN105611942A (en) | 2016-05-25 |
| TW201536314A (en) | 2015-10-01 |
| AU2014277981A1 (en) | 2016-01-07 |
| US20200113991A1 (en) | 2020-04-16 |
| AU2014277981B2 (en) | 2019-06-20 |
| US20210145956A1 (en) | 2021-05-20 |
| US20170304423A1 (en) | 2017-10-26 |
| US20160120968A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289821A (en) | Compositions and methods for immunotherapy | |
| HK1220387A1 (en) | Compositions and methods for immunotherapy | |
| HK1218837A1 (en) | Compositions and methods | |
| HK1218560A1 (en) | Compositions and methods | |
| GB2520795B (en) | Compositions and methods | |
| HUE048666T2 (en) | Agricultural endophyte-plant compositions, and methods of use | |
| GB201308072D0 (en) | Compositions and methods | |
| IL285527A (en) | Compositions and methods for immunotherapy | |
| IL239840A0 (en) | Polymyxins, compositions, methods of making and methods of use | |
| EP2986316A4 (en) | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | |
| PL2988764T3 (en) | Anti-dandruff compositions, and methods of use thereof | |
| GB201305813D0 (en) | Compositions and methods | |
| HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| SG11201510166YA (en) | Compositions and methods of immunizing against c. difficile | |
| GB201322617D0 (en) | Methods and compositions | |
| GB201312393D0 (en) | Compositions and Methods |